Kayce Blumenstock^1,2, Vandana Zaman^2,3, Camille Green³, Narendra L. Banik^1,2,3, Azizul Haque^1,2,3,*

BIOCELL, Vol.49, No.10, pp. 1859-1871, 2025, DOI:10.32604/biocell.2025.068773 - 22 October 2025

Abstract Fc Receptor-Like 1 (FCRL1), a member of the FCRL family, contains two immunoreceptor tyrosine-based activation motifs (ITAMs) in its cytoplasmic domain and plays a critical role in B-cell biology. Its expression begins in pre-B-cells, dynamically shifts during B-cell development, and contributes to the regulation of human B-cell activation. Notably, FCRL1 is overexpressed in subsets of naive and memory B-cells, as well as in malignant B-cells, including those in diffuse large B-cell lymphoma (DLBCL), an aggressive and often treatment-resistant hematological malignancy. Among FCRL family members, FCRL1 stands out as a promising immunotherapeutic target due to its More >

Sotirios Charalampos Diamantoudis^1,#,*, Androulla N. Miliotou^2,#, Eleftheria Galatou², Stergiani Telliou³, Konstantinos Sideris⁴, Nikolaos Grigoriadis¹, Ioannis S. Vizirianakis^1,2,*

BIOCELL, Vol.49, No.10, pp. 1799-1858, 2025, DOI:10.32604/biocell.2025.067216 - 22 October 2025

Abstract Hematological cancer stem cells (HCSCs) is a subpopulation of cells within hematological cancers that, through their characteristics, enhance malignancy and render their therapy more challenging. By uncovering the underlying mechanisms behind characteristic properties such as self-renewal, immune evasion, and conventional therapy resistance, as well as the major differences between other cancers and physiological cells, new and alternative targets can be assessed for use in existing and novel immunotherapeutic interventions. Through the evaluation of the existing literature, one can realize that there have already been several studies addressing the use of stem cell transplantation (SCT), monoclonal More > Graphic Abstract

Norbert Nass^1,2,#, Mohamad-Kamal Yaakoub^1,#, Alexandra-Victorita Simion³, Hartmut Kroll⁴, Sabine Westphal³, Judith Pannier¹, Gerhard Behre^1,*

Oncology Research, Vol.33, No.10, pp. 2923-2935, 2025, DOI:10.32604/or.2025.067561 - 26 September 2025

Abstract Background: Patients with hemato-oncological malignancies may respond insufficiently to vaccination, especially in terms of antibody titer. The antibody response depends on the type of malignancy as well as the type and timing of treatment. We intended to evaluate this using real-world data from patients of our regional hospital. This study also considers the role of immune status, including T-cell activation markers, in predicting vaccination success. Methods: Seventeen patients of our hospital having a hematological malignancy were included in this study, including myeloma, lymphoma, as well as acute myeloid leukemia (AML) and chronic lymphoid leukemia (CLL).… More >

Filomena Emanuela Laddaga¹, Pamela Pinto², Bruna Daraia², Antonio D’amato^3,4, Stella D’oronzo^3,5, Stefano Martinotti^3,6,*, Francesco Gaudio^2,3,*

BIOCELL, Vol.49, No.7, pp. 1185-1206, 2025, DOI:10.32604/biocell.2025.063572 - 25 July 2025

Abstract Checkpoint inhibitors, particularly programmed cell death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors, have significantly advanced the treatment of Hodgkin lymphoma (HL), especially in relapsed or refractory cases. However, challenges such as resistance, immune-related adverse events (irAEs), and the need for effective patient selection remain. This review aims to explore the mechanisms of resistance to checkpoint inhibitors, including alterations in the tumor microenvironment, loss of antigen presentation, and T-cell exhaustion. Overcoming resistance may involve combination therapies, such as pairing PD-1 inhibitors with other immune checkpoint inhibitors or targeted therapies like Brentuximab vedotin. Additionally, next-generation inhibitors targeting molecules like More >

Weiwei Chen¹, Xiaodie Zhou², Huiyu Li¹, Yuchen Yang¹, Lu Lu¹, Chunyan Zhu¹, Rong Fang¹, Xiaoyuan Chu¹, Shuping Zhou^3,*, Qian Sun^1,*

Oncology Research, Vol.33, No.8, pp. 2123-2139, 2025, DOI:10.32604/or.2025.063484 - 18 July 2025

Abstract Background: Primary bone marrow diffuse large B-cell lymphoma (PBM-DLBCL) represents an uncommon yet clinically aggressive hematologic malignancy. Despite its significant clinical impact, this entity lacks standardized diagnostic criteria in current WHO classifications. Methods: We performed a retrospective analysis of 55 PBM-DLBCL cases from our institutional database and published literature (2001–2022) to characterize disease features and identify prognostic factors, with particular focus on assessing how different treatment regimens influence therapeutic efficacy and long-term outcomes. Results: The data suggested a potential link between international prognostic index (IPI) scores and poorer survival, albeit without conclusive statistical evidence (p = More >

YONGFENG CHENG¹, YIPING SHEN², YUNFEI ZHANG¹, HAILIQIGULI NURIDING¹, XUEMEI WANG¹, CHUNYAN FAN¹, GULIBAHA MAIMAITI¹, YU LIU¹, YINGBIN YUE¹, DANLU LI¹, MEI YAN^1,*

Oncology Research, Vol.33, No.5, pp. 1173-1187, 2025, DOI:10.32604/or.2025.057842 - 18 April 2025

Abstract Background: The growth of the B-cell lymphoma subtype, Hodgkin lymphoma (HL), is associated with increased autophagy. A mycobacterial antigen, Ag85, has been reported to inhibit cell autophagy under a variety of conditions. Whether Ag85 could inhibit autophagy in HL is unknown. Methods: Lymph node samples from patients with HL and healthy controls were collected to assess proliferation and autophagy. The human HL cell line, L-428, was cultured and subjected to Ag85B treatment. Autophagy in L-428 cells was evaluated through western blotting analysis, immunohistochemistry, and transmission electron microscopy. Apoptosis in these cells was measured using flow… More >

DEMEI FENG^1,#, SHENRUI BAI^1,#, GUANJUN CHEN¹, BIBO FU¹, CAILU SONG¹, HAILIN TANG¹, LIANG WANG^2,*, HUA WANG^1,*

Oncology Research, Vol.33, No.4, pp. 965-974, 2025, DOI:10.32604/or.2024.057065 - 19 March 2025

Abstract Objectives: The optimal treatment strategy for early-stage natural killer/T-cell lymphoma (NKTCL) remains unclear. This study aimed to evaluate and compare the clinical outcomes and adverse events (AEs) associated with two treatment regimens for early-stage NKTCL: pegaspargase with concurrent radiation therapy (P+CCRT) and pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) with sequential radiation therapy (SERT). Propensity score matching (PSM) was employed to ensure balanced comparison between these regimens. Methods: We assessed the efficacy of P+CCRT from a phase II trial and P-GEMOX combined with SERT using real-world data. PSM was conducted at a 1:1 ratio with a caliper… More >

JESSIE REYES-CARMONA^*

Oncology Research, Vol.33, No.2, pp. 301-307, 2025, DOI:10.32604/or.2024.053764 - 16 January 2025

Abstract The B lymphoma Mo-MLV insertion region 1 homolog (Bmi-1) protein of the polycomb complex is an essential mediator of the epigenetic transcriptional silencing by the chromatin structure. It has been reported to be crucial for homeostasis of the stem cells and tumorigenesis. Though years of investigation have clarified Bmi-1’s transcriptional regulation, post-translational modifications, and functions in controlling cellular bioenergetics, pathologies, and DNA damage response, the full potential of this protein with so many diverse roles are still unfulfilled. Bmi-1 is overexpressed in many human malignancies. Unraveling the Bmi-1’s precise functional role in head and neck… More >

WEI ZHANG^1,3,#, WEICHENG WANG^1,#, RUI WANG¹, XIAO HAN¹, LIJUN ZHU¹, WENJIE GUO^2,*, YANHONG GU^1,*

Oncology Research, Vol.33, No.1, pp. 225-234, 2025, DOI:10.32604/or.2024.050047 - 20 December 2024

Abstract Background: As a novel blocker of vascular endothelial growth factor receptor (VEGFR), fruquintinib has been approved for treating colorectal cancer (CRC). However, its dosage and therapeutic efficacy are limited by its widespread adverse reactions. Venetoclax, recognized as the initial inhibitor of B-cell lymphoma protein 2 (BCL2), has shown potential in boosting the effectiveness of immunotherapy against CRC. This study investigated the efficacy and mechanisms of fruquintinib combined with venetoclax in treating CRC. Methods and Materials: We developed a colon cancer mouse model with the CT26 colon cell line to demonstrate fruquintinib and venetoclax’s efficacy against tumors.… More > Graphic Abstract

WEN YANG, BIN TANG, DAN XU, WENXIU YANG^*

Oncology Research, Vol.33, No.1, pp. 199-212, 2025, DOI:10.32604/or.2024.050036 - 20 December 2024

Abstract Background: The prognostic significance of the chemokine receptor CCR7 in diffuse large B-cell lymphoma (DLBCL) has been reported previously. However, the detailed mechanisms of CCR7 in DLBCL, particularly regarding its interaction with lenalidomide treatment, are not fully understood. Methods: Our study utilized bioinformatics approaches to identify hub genes in SU-DHL-2 cell lines treated with lenalidomide compared to control groups. Immunohistochemical data and clinical information from 122 patients with DLBCL were analyzed to assess the correlation of CCR7 and p-ERK1/2 expression with the prognosis of DLBCL. Furthermore, in vitro and in vivo experiments were conducted to clarify the… More > Graphic Abstract